Canaccord Genuity reaffirmed their positive rating on shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) in a report issued on Monday. The firm currently has a $73.00 target price on the stock, up from their previous target price of $65.00.

Several other brokerages also recently issued reports on AERI. Stifel Nicolaus boosted their price target on shares of Aerie Pharmaceuticals from $55.00 to $65.00 and gave the company a buy rating in a report on Tuesday, July 4th. Zacks Investment Research downgraded shares of Aerie Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, July 11th. Cantor Fitzgerald reissued an overweight rating and set a $62.00 price target (up previously from $56.00) on shares of Aerie Pharmaceuticals in a report on Thursday, July 20th. BidaskClub raised shares of Aerie Pharmaceuticals from a strong sell rating to a sell rating in a report on Monday, July 24th. Finally, HC Wainwright set a $69.00 price target on shares of Aerie Pharmaceuticals and gave the company a buy rating in a report on Wednesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $68.92.

Aerie Pharmaceuticals (NASDAQ:AERI) opened at 64.05 on Monday. The stock’s market cap is $2.33 billion. Aerie Pharmaceuticals has a 12 month low of $32.05 and a 12 month high of $66.10. The firm’s 50-day moving average is $55.46 and its 200-day moving average is $50.89.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings data on Tuesday, August 1st. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.02. On average, equities analysts forecast that Aerie Pharmaceuticals will post ($2.59) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Aerie Pharmaceuticals, Inc. (AERI) Given Positive Rating at Canaccord Genuity” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://theolympiareport.com/2017/10/17/aerie-pharmaceuticals-inc-aeri-given-positive-rating-at-canaccord-genuity.html.

Several hedge funds have recently modified their holdings of AERI. Wells Fargo & Company MN lifted its holdings in shares of Aerie Pharmaceuticals by 22.1% during the first quarter. Wells Fargo & Company MN now owns 26,273 shares of the company’s stock worth $1,191,000 after buying an additional 4,758 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Aerie Pharmaceuticals by 34.8% during the first quarter. Bank of New York Mellon Corp now owns 265,076 shares of the company’s stock worth $12,021,000 after buying an additional 68,360 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Aerie Pharmaceuticals by 8.3% during the first quarter. Swiss National Bank now owns 46,800 shares of the company’s stock worth $2,122,000 after buying an additional 3,600 shares during the last quarter. UBS Asset Management Americas Inc. lifted its holdings in shares of Aerie Pharmaceuticals by 97.3% during the first quarter. UBS Asset Management Americas Inc. now owns 12,430 shares of the company’s stock worth $564,000 after buying an additional 6,130 shares during the last quarter. Finally, Karp Capital Management Corp acquired a new position in shares of Aerie Pharmaceuticals during the first quarter worth approximately $213,000. Institutional investors own 94.64% of the company’s stock.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.